ArticleNPJ precision oncology2025
Prkci acts a pro-proliferation factor in colorectal cancer.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Colorectal cancer (CRC) is a common malignancy with high mortality, and its treatment remains challenging in advanced stages. Protein kinase C iota (Prkci), a member of the atypical PKC family, is implicated in several cancers, yet its role in CRC is unclear. Here, we report that Prkci is overexpressed in CRC and correlates with poor prognosis. Functional assays showed that Prkci enhances proliferation and metabolic activity, while its knockout suppresses tumor growth both in vitro and in vivo. Mechanistically, Prkci interacts with and phosphorylates c-Myc at serine 21, thereby inhibiting its ubiquitin-mediated degradation and stabilizing the protein. The pro-proliferative effect of Prkci is dependent on c-Myc S21 phosphorylation. In mouse models, deletion of Prkci significantly delayed tumor growth and improved survival. These findings identify Prkci as a key regulator of CRC progression via post-translational stabilization of c-Myc, highlighting it as a potential therapeutic target in colorectal cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.